These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2091324)

  • 1. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography.
    Nagasawa H; Kogure K; Kawashima K; Ido T; Itoh M; Hatazawa J
    Tohoku J Exp Med; 1990 Nov; 162(3):225-33. PubMed ID: 2091324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
    Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
    Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prolonged co-dergocrine mesylate (Hydergine) treatment on local cerebral glucose uptake in aged Fischer 344 rats.
    Meier-Ruge W
    Arch Gerontol Geriatr; 1986 Apr; 5(1):65-77. PubMed ID: 3718073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased cerebral glucose metabolism associated with mental deterioration in multi-infarct dementia.
    Meguro K; Doi C; Ueda M; Yamaguchi T; Matsui H; Kinomura S; Itoh M; Yamada K; Sasaki H
    Neuroradiology; 1991; 33(4):305-9. PubMed ID: 1922743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-dergocrine, cerebral glucose utilization and maze performance in middle-aged rats.
    Walovitch RC; Ingram DK; Spangler EL; London ED
    Pharmacol Biochem Behav; 1987 Jan; 26(1):95-101. PubMed ID: 3562504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
    Köberle S; Spiegel R
    Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of asthmatic patients using an alpha-adrenergic receptor blocking agent, co-dergocrine mesylate ('Hydergine').
    Kitamura S
    Pharmatherapeutica; 1980; 2(5):330-6. PubMed ID: 7433473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients].
    Mies R; Lang R; Weidinger G; Welzel D
    Arzneimittelforschung; 1983; 33(5):771-3. PubMed ID: 6683557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of the ratio of cerebral oxygen consumption to glucose utilization by positron emission tomography: its consistency with the values determined by the Kety-Schmidt method in normal volunteers.
    Hatazawa J; Ito M; Matsuzawa T; Ido T; Watanuki S
    J Cereb Blood Flow Metab; 1988 Jun; 8(3):426-32. PubMed ID: 3259242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral glucose metabolism in aging rodents: effects of co-dergocrine.
    London ED; Walovitch RC
    J Pharmacol; 1985; 16 Suppl 3():73-84. PubMed ID: 4094450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Hydergine on platelet deposition on "active" human carotid artery lesions and platelet function.
    Steurer G; Fitscha P; Ettl K; Sinzinger H
    Thromb Res; 1989 Sep; 55(5):577-89. PubMed ID: 2814944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical glucose metabolism in psychiatric wandering patients with vascular dementia.
    Meguro K; Yamaguchi S; Yamazaki H; Itoh M; Yamaguchi T; Matsui H; Sasaki H
    Psychiatry Res; 1996 May; 67(1):71-80. PubMed ID: 8797244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-dergocrine plasma concentrations and blood pressure changes in hypertensive patients during therapy with slow-release co-dergocrine mesylate.
    Woodcock BG; Herrmann W; Habedank WD
    Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):63-5. PubMed ID: 1551748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of co-dergocrine on platelet aggregation.
    Santos RO; Rodrigues R
    Braz J Med Biol Res; 1990; 23(3-4):325-7. PubMed ID: 2094545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and antihypertensive effects of co-dergocrine (Hydergine) in rats.
    Siegl H
    J Pharmacol; 1985; 16 Suppl 3():113-27. PubMed ID: 3912625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Brain glucose metabolism in a patient with Creutzfeldt-Jakob disease measured by positron emission tomography].
    Shishido F; Uemura K; Inugami A; Tomura N; Higano S; Fujita H; Tabata K; Sasaki H; Murakami M; Kanno I
    Kaku Igaku; 1990 Jun; 27(6):649-54. PubMed ID: 2214329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical hypometabolism and crossed cerebellar diaschisis suggest subcortically induced disconnection in CADASIL: an 18F-FDG PET study.
    Tatsch K; Koch W; Linke R; Poepperl G; Peters N; Holtmannspoetter M; Dichgans M
    J Nucl Med; 2003 Jun; 44(6):862-9. PubMed ID: 12791811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the cardiovascular effects of co-derocrine (Hydergine).
    Clark BJ; Bucher T; Waite R
    J Pharmacol; 1985; 16 Suppl 3():101-11. PubMed ID: 2869189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative randomized study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease.
    Hartmann A
    Curr Med Res Opin; 1985; 9(7):475-9. PubMed ID: 4028808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cerebral blood flow and metabolism in multi-infarct dementia by positron emission tomography].
    Araki T
    Nihon Rinsho; 1993 Dec; 51 Suppl():492-7. PubMed ID: 8121035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.